JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M212087200 on February 3, 2003

J. Biol. Chem., Vol. 278, Issue 15, 13480-13486, April 11, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/15/13480    most recent
M212087200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, C. J.
Right arrow Articles by Wolf, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, C. J.
Right arrow Articles by Wolf, C. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase*

Colin J. HendersonDagger , Diana M. E. OttoDagger , Dianne Carrie, Mark A. Magnuson§, Aileen W. McLaren, Ian Rosewell, and C. Roland Wolf||

From the Cancer Research UK Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom

Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of a large number of endogenous compounds and the majority of ingested environmental chemicals, leading to their elimination and often to their metabolic activation to toxic products. This enzyme system therefore provides our primary defense against xenobiotics and is a major determinant in the therapeutic efficacy of pharmacological agents. To evaluate the importance of hepatic P450s in normal homeostasis, drug pharmacology, and chemical toxicity, we have conditionally deleted the essential electron transfer protein, NADH:ferrihemoprotein reductase (EC 1.6.2.4, cytochrome P450 reductase, CPR) in the liver, resulting in essentially complete ablation of hepatic microsomal P450 activity. Hepatic CPR-null mice could no longer break down cholesterol because of their inability to produce bile acids, and whereas hepatic lipid levels were significantly increased, circulating levels of cholesterol and triglycerides were severely reduced. Loss of hepatic P450 activity resulted in a 5-fold increase in P450 protein, indicating the existence of a negative feedback pathway regulating P450 expression. Profound changes in the in vivo metabolism of pentobarbital and acetaminophen indicated that extrahepatic metabolism does not play a major role in the disposition of these compounds. Hepatic CPR-null mice developed normally and were able to breed, indicating that hepatic microsomal P450-mediated steroid hormone metabolism is not essential for fertility, demonstrating that a major evolutionary role for hepatic P450s is to protect mammals from their environment.


* This work was supported by Cancer Research UK.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to the work.

§ Present address: Dept. of Molecular Physiology and Biophysics, Vanderbilt School of Medicine, 702 Light Hall, Nashville, TN 37232. E-mail: mark.magnuson@vanderbilt.edu.

Present address: Cancer Research UK Transgenic Services, Clare Hall Laboratories, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3LD, UK. E-mail: ian.rosewell@cancer.org.uk.

|| To whom correspondence should be addressed. Tel.: 01382-632621; Fax: 01382-669993; E-mail: roland.wolf@cancer.org.uk.


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding
Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity
Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. A. McLaughlin, L. J. Dickmann, C. R. Wolf, and C. J. Henderson
Functional Expression and Comparative Characterization of Nine Murine Cytochromes P450 by Fluorescent Inhibition Screening
Drug Metab. Dispos., July 1, 2008; 36(7): 1322 - 1331.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Dostalek, K. D. Hardy, G. L. Milne, J. D. Morrow, C. Chen, F. J. Gonzalez, J. Gu, X. Ding, D. A. Johnson, J. A. Johnson, et al.
Development of Oxidative Stress by Cytochrome P450 Induction in Rodents Is Selective for Barbiturates and Related to Loss of Pyridine Nucleotide-dependent Protective Systems
J. Biol. Chem., June 20, 2008; 283(25): 17147 - 17157.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
V. M. Arlt, M. Stiborova, C. J. Henderson, M. Thiemann, E. Frei, D. Aimova, R. Singh, G. Gamboa da Costa, O. J. Schmitz, P. B. Farmer, et al.
Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice
Carcinogenesis, March 1, 2008; 29(3): 656 - 665.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Huang, V. Agrawal, K. M. Giacomini, and W. L. Miller
Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations
PNAS, February 5, 2008; 105(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Q.-Y. Zhang, L. S. Kaminsky, D. Dunbar, J. Zhang, and X. Ding
Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine
Drug Metab. Dispos., September 1, 2007; 35(9): 1617 - 1623.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding
Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice
Cancer Res., August 15, 2007; 67(16): 7825 - 7832.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. D. Finn, A. W. McLaren, D. Carrie, C. J. Henderson, and C. R. Wolf
Conditional Deletion of Cytochrome P450 Oxidoreductase in the Liver and Gastrointestinal Tract: A New Model for Studying the Functions of the P450 System
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 40 - 47.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Gu, C.-S. Chen, Y. Wei, C. Fang, F. Xie, K. Kannan, W. Yang, D. J. Waxman, and X. Ding
A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 9 - 17.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. M. Mutch, V. Crespy, J. Clough, C. J. Henderson, S. Lariani, R. Mansourian, J. Moulin, C. R. Wolf, and G. Williamson
Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G63 - G72.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Weng, C. C. DiRusso, A. A. Reilly, P. N. Black, and X. Ding
Hepatic Gene Expression Changes in Mouse Models with Liver-specific Deletion or Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: MECHANISTIC IMPLICATIONS FOR THE REGULATION OF MICROSOMAL CYTOCHROME P450 AND THE FATTY LIVER PHENOTYPE
J. Biol. Chem., September 9, 2005; 280(36): 31686 - 31698.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. L. Miller
Minireview: Regulation of Steroidogenesis by Electron Transfer
Endocrinology, June 1, 2005; 146(6): 2544 - 2550.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. J. Pass, D. Carrie, M. Boylan, S. Lorimore, E. Wright, B. Houston, C. J. Henderson, and C. R. Wolf
Role of Hepatic Cytochrome P450s in the Pharmacokinetics and Toxicity of Cyclophosphamide: Studies with the Hepatic Cytochrome P450 Reductase Null Mouse
Cancer Res., May 15, 2005; 65(10): 4211 - 4217.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Liao, V. G. Zgoda, B. P. Murray, and M. A. Correia
Vacuolar Degradation of Rat Liver CYP2B1 in Saccharomyces cerevisiae: Further Validation of the Yeast Model and Structural Implications for the Degradation of Mammalian Endoplasmic Reticulum P450 Proteins
Mol. Pharmacol., May 1, 2005; 67(5): 1460 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. M. Arlt, M. Stiborova, C. J. Henderson, M. R. Osborne, C. A. Bieler, E. Frei, V. Martinek, B. Sopko, C. R. Wolf, H. H. Schmeiser, et al.
Environmental Pollutant and Potent Mutagen 3-Nitrobenzanthrone Forms DNA Adducts after Reduction by NAD(P)H:Quinone Oxidoreductase and Conjugation by Acetyltransferases and Sulfotransferases in Human Hepatic Cytosols
Cancer Res., April 1, 2005; 65(7): 2644 - 2652.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
M. P. Duarte, B. B. Palma, A. A. Gilep, A. Laires, J. S. Oliveira, S. A. Usanov, J. Rueff, and M. Kranendonk
The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation
Mutagenesis, March 1, 2005; 20(2): 93 - 100.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Gu, H. Cui, M. Behr, L. Zhang, Q.-Y. Zhang, W. Yang, J. A. Hinson, and X. Ding
In Vivo Mechanisms of Tissue-Selective Drug Toxicity: Effects of Liver-Specific Knockout of the NADPH-Cytochrome P450 Reductase Gene on Acetaminophen Toxicity in Kidney, Lung, and Nasal Mucosa
Mol. Pharmacol., March 1, 2005; 67(3): 623 - 630.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Wu, J. Gu, H. Cui, Q.-Y. Zhang, M. Behr, C. Fang, Y. Weng, K. Kluetzman, P. J. Swiatek, W. Yang, et al.
Transgenic Mice with a Hypomorphic NADPH-Cytochrome P450 Reductase Gene: Effects on Development, Reproduction, and Microsomal Cytochrome P450
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 35 - 43.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
C. J. Henderson and C. R. Wolf
Transgenic Analysis of Human Drug-Metabolizing Enzymes: Preclinical Drug Development and Toxicology
Mol. Interv., September 1, 2003; 3(6): 331 - 343.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Gu, Y. Weng, Q.-Y. Zhang, H. Cui, M. Behr, L. Wu, W. Yang, L. Zhang, and X. Ding
Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene: IMPACT ON PLASMA CHOLESTEROL HOMEOSTASIS AND THE FUNCTION AND REGULATION OF MICROSOMAL CYTOCHROME P450 AND HEME OXYGENASE
J. Biol. Chem., July 3, 2003; 278(28): 25895 - 25901.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.